Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease

NCT00909545 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT00909545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00909545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2009
Completion date
February 29, 2012
Enrollment
99 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease